HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
AUTOIMMUNITY REVIEWS, cilt.17, sa.12, ss.1153-1168, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 17 Sayı: 12
- Basım Tarihi: 2018
- Doi Numarası: 10.1016/j.autrev.2018.05.012
- Dergi Adı: AUTOIMMUNITY REVIEWS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1153-1168
- Hacettepe Üniversitesi Adresli: Evet
Özet
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3].